Molecular Nature of the Vitamin D Receptor and its Role in Regulation of Gene Expression

Reviews in Endocrine and Metabolic Disorders

Volumn 2, Issue 2, 2001, Pages 203-216

  Jurutka, Peter W ^a   Whitfield, G Kerr ^a   Hsieh, Jui Cheng ^a   Thompson, Paul D ^a   Haussler, Carol A ^a   Haussler, Mark R ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

1,25 dihydroxyvitamin D3 hormone; Bone mineral density; Calcium homeostasis; Hereditary hypocalcemic vitamin D resistant rickets; Nuclear receptor superfamily; Osteoporosis; Retinoid X receptor

Indexed keywords

CALCITRIOL RECEPTOR; VITAMIN D;

ANIMAL; BIOSYNTHESIS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 0035320083     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010062929140     Document Type: Article

References (98)

1. Haussler MR, Whitfield GK, Haussler CA, Hsieh J-C, Thompson PD, Selznick SH, Encinas Dominguez C, Jurutka PW. The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13:325-349.
2. Brooks MH, Bell NH, Love L, Stern PH, Orfei E, Queener SF, Hamstra AJ, DeLuca HF. Vitamin-D-dependent rickets type II. Resistance of target organs to 1,25-dihydroxyvitamin D. N Engl J Med 1978;298:996-999.
3. Hewison M, Rut AR, Kristjansson K, Walker RE, Dillon MJ, Hughes MR, O'Riordan JLH. Tissue resistance to 1,25-dihydroxyvitamin D without a mutation of the vitamin D receptor gene. Clin Endocrinol (Oxf) 1993;39:663-670.
4. Manolagas SC, Yu X-P, Girasole G, Bellido T. Vitamin D and the hematolymphopoietic tissue: A 1994 update. Sem Nephrol 1994;14:129-143.
5. 3. J Steroid Biochem Molec Biol 1995;53:599-602.
6. Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, Kawakami T, Arioka K, Sato H, Uchiyama Y, Masushige S, Fukamizu A, Matsumoto T, Kato S. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997;16:391-396.
7. Li YC, Pirro AE, Amling M, Delling G, Baron R, Bronson R, Demay MB. Targeted ablation of the vitamin D receptor: An animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 1997;94:9831-9835.
8. Li YC, Amling M, Pirro AE, Priemel M, Meuse J, Baron R, Delling G, Demay MB. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998;139:4391-4396.
9. al-Aqeel A, Ozand P, Sobki S, Sewairi W, Marx S. The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII). Clin Endocrinol (Oxf) 1993;39:229-237.
10. Takeda S, Yoshizawa T, Fukumoto S, Nagai Y, Murayama H, Matsumoto T, Kato S, Fujita T. Bone metabolism and in vitro osteoclast formation in VDR knock-out mice. J Bone Miner Res 1997;12, (Suppl. 1):S110 (abstract 32).
11. Jimi E, Nakamura I, Amano H, Taguchi Y, Tsurukai T, Tamura M, Takahashi N, Suda T. Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 1996;137:2187-2190.
12. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/ RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602.
13. Ducy P, Karsenty G. Genetic control of cell differentiation in the skeleton. Curr Opin Cell Biol 1998;10:614-619.
14. 3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): Receptor-mediated maturation to macrophage-like cells. J Cell Biol 1984;98: 391-398.
15. Wientroub S, Winter CC, Wahl SM, Wahl LM. Effect of vitamin D deficiency on macrophage and lymphocyte function in the rat. Calcif Tissue Int 1989;44:125-130.
16. 3 which mediates rapid activation of protein kinase C. J Bone Miner Res 1998;13:1353-1359.
17. Norman AW. Receptors for 1alpha,25(OH)2D3: past, present, and future. J Bone Miner Res 1998;13:1360-1369.
18. Whitfield GK, Jurutka PW, Haussler CA, Haussler MR. Steroid hormone receptors: Evolution, ligands and molecular basis of biologic function. J Cell Biochem 2000;32/33(Suppl.):110-122.
19. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-Å. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-5930.
20. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA. Prediction of bone density from vitamin D receptor alleles. Nature 1994;367:284-287.
21. Houston LA, Grant SF, Reid DM, Ralston SH. Vitamin D receptor polymorphism, bone mineral density, and osteoporotic vertebral fracture: Studies in a UK population. Bone 1996;18:249-252.
22. Ingles SA, Haile RW, Henderson BE, Kolonel LN, Nakaichi G, Shi C-Y, Yu MC, Ross RK, Coetzee GA. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: Implications for association studies. Cancer Epidemiol Biomarkers Prev 1997;6:93-98.
23. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-170.
24. Gingras A-C, Raught B, Sonenberg N. eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation. Ann Rev Biochem 1999;68:913-963.
25. Deo RC, Bonanno JB, Sonenberg N, Burley SK. Recognition of polyadenylate RNA by the poly(A)-binding protein. Cell 1999;98:835-845.
26. 3-elicited VDR transactivation ability. Bone 1998;23 (Suppl. 5):S198 (abstract 1205).
27. Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh J-C, Zitzer H, Tavakkoli P, Galligan MA, Dang HT, Haussler CA, Haussler MR. The polymorphic N-terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol 2000;14:401-420.
28. Arai H, Miyamoto K-I, Taketani Y, Yamamoto H, Iemori Y, Morita K, Tonai T, Nishisho T, Mori S, Takeda E. A vitamin D receptor gene polymorphism in the translation initiation codon: Effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res 1997;12:915-921.
29. Gross C, Eccleshall TR, Malloy PJ, Villa ML, Marcus R, Feldman D. The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J Bone Miner Res 1996;11:1850-1855.
30. Ferrari S, Rizzoli R, Manen D, Slosman D, Bonjour JP. Vitamin D receptor gene start codon polymorphisms (FokI) and bone mineral density: Interaction with age, dietary calcium, and 3′-end region polymorphisms. J Bone Miner Res 1998;13:925-930.
31. Yamamoto H, Miyamoto K, Li B, Taketani Y, Kitano M, Inoue Y, Morita K, Pike JW, Takeda E. The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine. J Bone Miner Res 1999;14:240-247.
32. Suh E, Chen L, Taylor J, Traber PG. A homeodomain protein related to caudal regulates intestine-specific gene transcription. Mol Cell Biol 1994;14:7340-7351.
33. Arai H, Miyamoto K, Yoshida M, Kubota M, Yamamoto H, Taketani Y, Yoshida S, Ikeda M, Takeda E. The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J Bone Miner Res 1999;14:S191 (abstract T084).
34. Miyamoto K-i, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, Inoue Y, Morita K, Takeda E, Pike JW. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol 1997;11:1165-1179.
35. Crofts L, Hancock MS, Morrison NA, Eisman JA. Multiple promoters direct the tissue-specific expression of novel N- terminal variant human vitamin D receptor gene transcripts. Proc Natl Acad Sci USA 1998;95:10529-10534.
36. Sunn KL, Cock T, Crofts LA, Eisman JA, Gardiner EM. Novel N-terminal variant of human viamin D receptor protein. J Bone Miner Res 1999;14, (Suppl. 1):S168 (Abstract 1146).
37. Subbarayan V, Kastner P, Mark M, Dierich A, Gorry P, Chambon P. Limited specificity and large overlap of the functions of the mouse RAR gamma 1 and RAR gamma 2 isoforms. Mech Dev 1997;66:131-142.
38. Abel ED, Boers ME, Pazos-Moura C, Moura E, Kaulbach H, Zakaria M, Lowell B, Radovick S, Liberman MC, Wondisford F. Divergent roles for thyroid hormone receptor beta isoforms in the endocrine axis and auditory system. J Clin Invest 1999;104:291-300.
39. Saga Y, Kobayashi M, Ohta H, Murai N, Nakai N, Oshima M, Taketo MM. Impaired extrapyramidal function caused by the targeted disruption of retinoid X receptor RXRgamma1 isoform. Genes Cells 1999;4:219-228.
40. Haussler MR, Jurutka PW, Hsieh J-C, Thompson PD, Haussler CA, Selznick SH, Remus LS, Whitfield GK. Nuclear vitamin D receptor: Structure-function, phosphorylation and control of gene transcription. In: Feldman D, Glorieux FH, Pike JW, eds. Vitamin D. San Diego: Academic Press, 1997:149-177.
41. Hsieh J-C, Shimizu Y, Minoshima S, Shimizu N, Haussler CA, Jurutka PW, Haussler MR. Novel nuclear localization signal between the two DNA-binding zinc fingers in the human vitamin D receptor. J Cell Biochem 1998;70:94-109.
42. 3 receptor identifying C-terminal amino acids required for transcriptional activation that are functionally dissociated from hormone binding, heterodimeric DNA binding and interaction with basal transcription factor IIB, in vitro. J Biol Chem 1997;272:14592-14599.
43. Kraichely DM, Collins JJ, 3rd, DeLisle RK, MacDonald PN. The autonomous transactivation domain in helix H3 of the vitamin D receptor is required for transactivation and coactivator interaction. J Biol Chem 1999;274:14352-14358.
44. Shao D, Lazar MA. Modulating nuclear receptor function: May the phos be with you. J Clin Invest 1999;103:1617-1618.
45. Jones BB, Jurutka PW, Haussler CA, Haussler MR, Whitfield GK. Vitamin D receptor phosphorylation in transfected ROS 17/2.8 cells is localized to the N-terminal region of the hormone-binding domain. Mol Endocrinol 1991;5:1137-1146.
46. Jurutka PW, Hsieh J-C, MacDonald PN, Terpening CM, Haussler CA, Haussler MR, Whitfield GK. Phosphorylation of serine 208 in the human vitamin D receptor: The predominant amino acid phosphorylated by casein kinase II, in vitro, and identification as a significant phosphorylation site in intact cells. J Biol Chem 1993;268:6791-6799.
47. 3 modulates phosphorylation of serine 205 in the human vitamin D receptor: Site-directed mutagenesis of this residue promotes alternative phosphorylation. Biochemistry 1994;33:4300-4311.
48. Jurutka PW, Hsieh J-C, Nakajima S, Haussler CA, Whitfield GK, Haussler MR. Human vitamin D receptor phosphorylation by casein kinase II at ser-208 potentiates transcriptional activation. Proc Natl Acad Sci USA 1996;93:3519-3524.
49. Hsieh J-C, Jurutka PW, Galligan MA, Terpening CM, Haussler CA, Samuels DS, Shimizu Y, Shimizu N, Haussler MR. Human vitamin D receptor is selectively phosphorylated by protein kinase C on serine 51, a residue crucial to its trans-activation function. Proc Natl Acad Sci USA 1991;88:9315-9319.
50. Hsieh J-C, Jurutka PW, Nakajima S, Galligan MA, Haussler CA, Shimizu Y, Shimizu N, Whitfield GK, Haussler MR. Phosphorylation of the human vitamin D receptor by protein kinase C: Biochemical and functional evaluation of the serine 51 recognition site. J Biol Chem 1993;268:15118-15126.
51. Rastinejad F, Perlmann T, Evans RM, Sigler PB. Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature 1995;375:203-211.
52. Rangarajan PN, Umesono K, Evans RM. Modulation of glucocorticoid receptor function by protein kinase A. Mol Endocrinol 1992;6:1451-1457.
53. 3: Modulation by phosphorylation. In: Norman AW, Bouillon R, Thomasset M, eds. Vitamin D: A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications. Berlin: Walter de Gruyter, 1994:209-216.
54. 3 receptor by cAMP-dependent protein kinase, in vitro, and in transfected COS-7 cells. Biochem Biophys Res Commun 1993;191:1089-1096.
55. 3 receptor. Biochim Biophys Acta 1993;1167:29-36.
56. Taneja R, Rochette-Egly C, Plassat JL, Penna L, Gaub MP, Chambon P. Phosphorylation of activation functions AF-1 and AF-2 of RARalpha and RARgamma is indispensable for differentiation of F9 cells upon retinoic acid and cAMP treatment. EMBO J 1997;16:6452-6465.
57. Ozono K, Liao J, Kerner SA, Scott RA, Pike JW The vitamin D-responsive element in the human osteocalcin gene: Association with a nuclear proto-oncogene enhancer. J Biol Chem 1990;265:21881-21888.
58. La Vista-Picard N, Hobbs PD, Pfahl M, Dawson MI, Pfahl M. The receptor-DNA complex determines the retinoid response: A mechanism for the diversification of the ligand signal. Mol Cell Biol 1996;16:4137-4146.
59. Staal A, van Wijnen AJ, Birkenhäger JC, Pols HAP, Prahl J, DeLuca H, Gaub M-P, Lian JB, Stein GS, van Leeuwen JPTM, Stein JL. Distinct conformations of vitamin D receptor/retinoid X receptor-α heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements for the osteocalcin and osteopontin genes. Mol Endocrinol 1996;10:1444-1456.
60. Koszewski NJ, Ashok S, Russell J. Turning a negative into a positive: Vitamin D receptor interactions with the avian parathyroid hormone response element. Mol Endocrinol 1999;13:455-465.
61. Sneddon WB, Bogado CE, Kiernan MS, Demay MB. DNA sequences downstream from the vitamin D response element of the rat osteocalcin gene are required for ligand-dependent transactivation. Mol Endocrinol 1997;11:210-217.
62. 3 24-hydroxylase gene. J Biol Chem 1996;271:30381-30385.
63. Candeliere GA, Jurutka PW, Haussler MR, St-Arnaud R. A composite element binding the vitamin D receptor, retinoid X receptor α, and a member of the CTF/NF-1 family of transcription factors mediates the vitamin D responsiveness of the c-fos promoter. Mol Cell Biol 1996;16:584-592.
64. Zugmaier G, Jager R, Grage B, Gottardis MM, Havemann K, Knabbe C. Growth-inhibitory effects of vitamin D analogs and retinoids on human pancreatic cancer cells. Br J Cancer 1996;73:1341-1346.
65. 3 are differentially modified by 9-cis-retinoic acid. Cancer Res 1996;56:623-632.
66. 3 are associated with enhanced activation of the vitamin D receptor. J Biol Chem 1995;270:10551-10558.
67. 3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology 1989;124:2645-2647.
68. 3. Mol Endocrinol 1995;9:1814-1824.
69. 3 receptor. J Biol Chem 1999;274:16838-16845.
70. 3 analogs and their 20-epi homologues with the vitamin D receptor. J Biol Chem 1997;272:3336-3345.
71. Nagpal S, Friant S, Nakshatri H, Chambon P. RARs and RXRs: Evidence for two autonomous transactivation domains (AF-1 and AF-2) and heterodimerization in vivo. EMBO J 1993;12:2349-2360.
72. McKenna NJ, Xu J, Nawaz Z, Tsai SY, Tsai M-J, O'Malley BW Nuclear receptor coactivators: Multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Molec Biol 1999;69:3-12.
73. 3 and inhibited by 9-cis retinoic acid: Evidence for allosteric receptor interactions. J Biol Chem 1998;273:8483-8491.
74. Whitfield GK, Hsieh J-C, Nakajima S, MacDonald PN, Thompson PD, Jurutka PW, Haussler CA, Haussler MR. A highly conserved region in the hormone binding domain of the human vitamin D receptor contains residues vital for heterodimerization with retinoid X receptor and for transcriptional activation. Mol Endocrinol 1995;9:1166-1179.
75. Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ, West BL. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 1998;280:1747-1749.
76. Xu L, Glass CK, Rosenfeld MG. Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev 1999;9:140-147.
77. Gill RK, Atkins LM, Hollis BW, Bell NH. Mapping the domains of the interaction of the vitamin D receptor and steroid receptor coactivator-1. Mol Endocrinol 1998;12:57-65.
78. Hong H, Kohli K, Garabedian MJ, Stallcup MR. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol 1997;17:2735-2744.
79. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 1997;90:569-580.
80. Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999;98:285-294.
81. 3 and thyroid hormone receptors and with derivatives of the retinoid X receptor that have altered transactivation properties. Mol Cell Biol 1999;19:5486-5494.
82. 3, and thyroid hormone receptors in mammalian cells. Genes Dev 1997;11:1381-1395.
83. Rachez C, Lemon BD, Suldan Z, Bromleigh V, Gamble M, Näär AM, Erdjument-Bromage H, Tempst P, Freedman LP. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 1999;398:824-828.
84. Blanco JCG, Wang I-M, Tsai SY, Tsai M-J, O'Malley BW, Jurutka PW, Haussler MR, Ozato K. Transcription factor TFIIB and the vitamin D receptor cooperatively activate ligand-dependent transcription. Proc Natl Acad Sci USA 1995;92:1535-1539.
85. MacDonald PN, Sherman DR, Dowd DR, Jefcoat SC, Jr., DeLisle RK. The vitamin D receptor interacts with general transcription factor IIB. J Biol Chem 1995;270:4748-4752.
86. DeLisle RK, MacDonald PN. Characterization of domains of the vitamin D receptor required for interaction with basal transcription factor IIB. Bone 1998;23, (Suppl. 5):S199 (abstract 1208).
87. Baudino TA, Kraichely DM, Jefcoat SC, Jr., Winchester SK, Partridge NC, MacDonald PN. Isolation and characterization of a novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription. J Biol Chem 1998;273:16434-16441.
88. Weiss RE, Xu J, Ning G, Pohlenz J, O'Malley BW, Refetoff S. Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone. EMBO J 1999;18:1900-1904.
89. Mackey SL, Heymont JL, Kronenberg HM, Demay MB. Vitamin D receptor binding to the negative human parathyroid hormone vitamin D response element does not require the retinoid X receptor. Mol Endocrinol 1996; 10:298-305.
90. Tagami T, Lutz WH, Kumar R, Jameson JL. The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators. Biochem Biophys Res Commun 1998;253:358-363.
91. Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, Toriyabe T, Kawabata M, Miyazono K, Kato S. Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999;283:1317-1321.
92. 3 in human monocytes and macrophages: A mechanism for the hypercalcemia of various granulomatoses. J Clin Endocrinol Metab 1997;82:2222-2232.
93. 3 analogs in the treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 1998;11:2-10.
94. Dawson-Hughes B, Harris SS, Finneran S. Calcium absorption on high and low calcium intakes in relation to vitamin D receptor genotype. J Clin Endocrinol Metab 1995;80:3657-3661.
95. Ferrari S, Rizzoli R, Chevalley T, Slosman D, Eisman JA, Bonjour JP. Vitamin-D-receptor-gene polymorphisms and change in lumbar-spine bone mineral density. Lancet 1995;345:423-424.
96. Park BS, Park JS, Lee DY, Youn JI, Kim IG. Vitamin D receptor polymorphism is associated with psoriasis. J Invest Dermatol 1999;112:113-116.
97. Feldman D. Androgen and vitamin D receptor gene polymorphisms: The long and short of prostate cancer risk. J Natl Cancer Inst 1997;89:109-111.
98. Ruggiero M, Pacini S, Aterini S, Fallai C, Ruggiero C, Pacini P. Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. Oncol Res 1998;10:43-46.